GlassScriptPhysician profile
Beverly Conder
NPI 1619084647
$7,679.70
in general payments reported to CMS, 2019-2025
21 companies · $3,493 in 2025
The $3,493 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,145 · 2022: $1,142 · 2023: $757 · 2024: $1,142 · 2025: $3,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,751 · Travel and Lodging: $1,601 · Education: $40.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,751.24 |
| Travel and Lodging | $1,600.90 |
| Education | $40.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,034.27 | 2021-2025 | Cardiomems, Triclip, Gallant |
| Janssen Pharmaceuticals, INC | $825.59 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $749.48 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $512.86 | 2021-2025 | Farxiga, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $425.08 | 2021-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $374.81 | 2022-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $299.52 | 2022-2025 | Jardiance |
| Pfizer INC. | $261.97 | 2021-2025 | |
| Amgen INC. | $236.75 | 2021-2024 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $181.07 | 2021-2025 | |
| Impulse Dynamics (USA) INC. | $165.99 | 2025 | Optimizer |
| Novo Nordisk INC | $110.77 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Scpharmaceuticals INC. | $109.60 | 2024-2025 | |
| Abiomed | $100.11 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $98.88 | 2021-2025 | Camzyos, Eliquis |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $50.57 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $47.76 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $28.54 | 2024 | |
| Cvrx, INC. | $25.68 | 2025 | Barostim Neo System |
| Heartflow, INC. | $23.50 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $16.90 | 2023 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Conder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.